SQZ News and Press, SQZ Biotechnologies Company From 12/01/21

Roche Accelerator Membership to Support Company’s Early Strategic Planning and Market Exploration in China SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initia...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4 th Annual Evercore ISI HealthCONx Conference on December 1st. Armon Sharei, Ph.D., Chief Executi...

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive Officer, wil...

SQZ™ AACs Demonstrate Synergistic Effects with Chemotherapy in HPV16+ Cancer Model SQZ™ eAPCs Engineered with Multiple mRNAs Drive Robust CD8+ T Cell Response and are Potentially Applicable to Broader HPV16+ Cancer Patient Population mRNA Engineered TILs Show Poten...

SQZ Biotechnologies (NYSE:SQZ): Q3 GAAP EPS of -$0.80 misses by $0.22. Revenue of $4.8M (-21.3% Y/Y) misses by $3.77M. Press Release As of September 30, 2021, the company had cash and cash equivalents of $164.3M and anticipates this will be sufficient to fund operating expenses and capital ex...

Highest Dose Monotherapy Data from Phase 1/2 Trial of SQZ-PBMC-HPV-101 Accepted for Oral Presentation at ESMO IO SQZ-PBMC-HPV-101 Advances into Combination with Checkpoint Inhibitors eAPC IND Submission Anticipated by Year-End 2021 Celiac Disease TAC Platform...

High Dose Monotherapy Cohort Clinical Data from the SQZ-PBMC-HPV-101 Trial Accepted for Oral Presentation at ESMO IO in December Cohorts in Combination with anti-PD-(L)1 and anti-CTLA-4 Open for Enrollment Combination Stage Initiation Triggers Milestone Payment from Ro...

Posters Detail Preclinical Data on SQZ ™ AAC and eAPC Platforms and Enhanced Tumor Infiltrating Lymphocytes SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will pres...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Chardan 5 th Annual Genetic Medicines Conference on October 4. Armon Sharei, Ph.D., Chief Executiv...

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Cantor Global Healthcare Conference on September 29. Armon Sharei, Ph.D., Chief Executive Officer, wil...